The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01323608

Recruitment Status : Unknown

Verified April 2011 by Weill Medical College of Cornell University.
Recruitment status was: Not yet recruiting

First Posted : March 25, 2011

Last Update Posted : April 19, 2011

View this study on Beta.ClinicalTrials.gov

Sponsor:

Information provided by:

Weill Medical College of Cornell University

Study Description

Brief Summary:

The purpose of this pilot study is to determine the effect of various doses of vitamin D supplementation on vitamin D stores and calcium excretion in the urine in subjects with Thalassemia Major (TM). Subjects with TM are routinely placed on vitamin D supplements because they frequently have osteoporosis (a condition in which bone tissue thins and loses density and strength) and low vitamin D stores. The amount of vitamin D supplementation that is required to raise vitamin D stores in optimal levels is not known in TM, and will be determined in this study. Finally, a recent study in TM has linked blood vitamin D levels to urine calcium excretion, which is a risk factor for kidney stones. Therefore, we want to determine changes in calcium excretion with various vitamin D doses and with increasing vitamin D stores. We plan to test 3 doses of vitamin D for 3 months in children and adults with TM. Changes in vitamin D blood levels and urinary calcium will be determined. The results of this pilot study will be used in future studies that will examine the effect of various doses of vitamin D supplementation in the treatment of osteoporosis in TM.

Condition or disease	Intervention/treatment	Phase
Thalassemia Major	Drug: Vitamin D3 Drug: Placebo	Phase 4

Show detailed description

Detailed Description:

Specific Aim: To determine the effect of various doses of vitamin D supplementation on serum concentration of 25 hydroxy vitamin D (25OHD) and urinary calcium excretion in adults and children with TM.

Hypothesis: Vitamin D supplementation at doses that result in serum 25OHD levels >30 ng/ml result in high rates of hypercalciuria (i.e. increased urinary calcium excretion) in children and adults with TM.

The pilot study will be performed at Weill Cornell Medical College, Payson 695.

Children and adults with TM, will be divided into 4 groups: "standard" vitamin D dose (equivalent to 400 IU/day), "intermediate" vitamin D dose (equivalent to 1000 IU/day), "high" vitamin D dose (equivalent to 2,000 IU/day) and a "placebo" group that will receive an inactive ingredient. 10 subjects will be assigned to each group. The duration of the study will be 3 months.
While some studies found no difference between vitamin D2 and D3, others suggest that vitamin D3 may be more advantageous in restoring 25 OHD concentrations. For these reasons, vitamin D3 will be used in this protocol.
Study schedule with study interventions and frequencies is set out below (see table). All 4 groups will adhere to the same schedule. After obtaining consent, subjects will have a "Baseline Visit", which will include: 1) a complete physical examination; 2) laboratory evaluation that includes measurement of 25OHD, which is the major circulating form of vitamin D and reflects the body's vitamin D stores. Additional blood and urine samples will be obtained for measurement of urinary calcium excretion and serum Calcium and parathyroid hormone (PTH); and 3) Dietary calcium intake questionnaire. 4) Start of study medication.
Subjects will then return every 2-4 weeks for routine blood transfusions and as required for the management of Thalassemia. To ensure compliance, study medications will be administered by study personnel during these routine visits. Vitamin D supplies will be packaged according to one week worth requirement, i.e. as 1,000 IU/day x 7days=7,000 IU for the "intermediate" vitamin D group. The dose that will be administered during these visits will depend on the interval between transfusions, i.e. 7,000 IU x 2weeks, for a subject of the "intermediate" dose who is transfused every two weeks.
At the end of 3 month treatment, subjects will have a final visit, that is also scheduled to coincide with a routine transfusion visit. Subjects will have the same evaluation and procedures as in "Baseline Visit" : 1) a complete physical examination; 2) fasting laboratory evaluation that includes measurement of 25OHD, urinary calcium excretion and serum Calcium and PTH; and 3) Dietary calcium intake questionnaire.
Subjects will be asked to take calcium supplementation at the dose of 500 mg daily for the 6-8 year old and 1,000 mg daily for the 9-18 year old subjects. This intervention will ensure adequate calcium intake in both groups.

All labs will be processed at the CTSC Core Lab. Study meds will be distributed by the central pharmacy. Investigational drug will be administered by study personnel during the transfusion visits to ensure compliance.

Eligible subjects will be assigned to a study group following a block type of enrollment. To ensure an equal, or near equal sex and age distribution, study groups will be matched according to sex and age. Half of the subjects in each group will be composed of pediatric subjects and the other half will be composed of adult subjects.

Study Schedule and Procedures:

Baseline visit: Physical Exam, 25OHD, Intact PTH & Serum Calcium, 24 hr & spot urine collection for Ca/Crea, Calcium intake questionnaire, Vitamin D Supplementation/Placebo.
Every 2-4 weeks: Administration of Vitamin D/Placebo
3 Month Visit: Physical Exam, 25OHD, Intact PTH & Serum Calcium, 24 hr & spot urine collection for Ca/Crea, Calcium intake questionnaire, and Vitamin D Supplementation/ Placebo.

Primary study endpoint:

Changes in 25OHD concentrations and calcium excretion with the various vitamin D3 doses will be determined at the end of the study and constitute the primary endpoints.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	40 participants
Allocation:	Non-Randomized
Intervention Model:	Parallel Assignment
Masking:	None (Open Label)
Primary Purpose:	Diagnostic
Official Title:	The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study
Study Start Date :	June 2011
Estimated Primary Completion Date :	June 2014
Estimated Study Completion Date :	December 2014

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Beta thalassemia

MedlinePlus related topics: Calcium Thalassemia Vitamin D

Drug Information available for: Cholecalciferol Vitamin D

Genetic and Rare Diseases Information Center resources: Thalassemia Beta-thalassemia

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Placebo Comparator: Placebo	Drug: Placebo Placebo
Experimental: Low Vitamin D Group Subjects in this group will receive the equivalent of 400 IU/day.	Drug: Vitamin D3 Vitamin D3 will be given at the equivalent of the following doses: 400, 1000, and 2000 IU/day.
Experimental: Intermediate Vitamin D group	Drug: Vitamin D3 Vitamin D3 will be given at the equivalent of the following doses: 400, 1000, and 2000 IU/day.
Experimental: High Vitamin D Group	Drug: Vitamin D3 Vitamin D3 will be given at the equivalent of the following doses: 400, 1000, and 2000 IU/day.

Outcome Measures

Primary Outcome Measures :

Vitamin D Dose Response Curve [ Time Frame: 3 Months ]
To perform a dose response curve for vitamin D supplementation study and determine the relationship between vitamin D doses and serum 25OHD concentrations and urinary calcium excretion in children and adults with TM.

Secondary Outcome Measures :

Vitamin D Dose Response Curve [ Time Frame: 3 Months ]
To determine changes in serum calcium and PTH concentrations with various vitamin D doses

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	6 Years to 60 Years (Child, Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Thalassemia Major (TM)
25 OHD: 15-29 ng/ml
Age 6 to 60 years
Albumin corrected serum Calcium: Normal (8.5-10.5 mg/dl)

Exclusion Criteria:

Other thalassemia syndromes
25 OHD concentrations < 15 ng/ml or ≥30 ng/ml
Subjects younger than 6 years
Hypoparathyroidism
Abnormal albumin corrected serum Ca (i.e. total calcium <8.5 or > 10.5 mg/dl)
Medications that may adversely affect vitamin D metabolism (anticonvulsants) or absorption
End stage renal, heart, or liver disease
History of Nephrolithiasis or Nephrocalcinosis
Diseases associated with hypercalciuria (ie. Sarcoidosis, Cushing syndrome, and Wilson disease to name a few)

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01323608

Contacts

Layout table for location contacts

Contact: Maria Vogiatzi, MD	212-746-3462	mvogiatz@med.cornell.edu
Contact: Patricia J Giardina, MD	212-746-3415	pjgiardi@med.cornell.edu

Locations

Layout table for location information

United States, New York
Weill Cornell Medical College
New York, New York, United States, 10065
Contact: Maria Vogiatzi, MD 212-746-3462 mvogiatz@med.cornell.edu
Contact: Patricia J Giardina, MD 212-746-3415 pjgiardi@med.cornell.edu
Principal Investigator: Maria Vogiatzi, MD

Sponsors and Collaborators

Weill Medical College of Cornell University

Investigators

Layout table for investigator information

Principal Investigator:	Maria Vogiatzi, MD	Weill Medical College of Cornell University

More Information

Layout table for additonal information

Responsible Party:	Maria Vogiatzi, MD, Weill Cornell Medical College
ClinicalTrials.gov Identifier:	NCT01323608
Other Study ID Numbers:	1102011521
First Posted:	March 25, 2011 Key Record Dates
Last Update Posted:	April 19, 2011
Last Verified:	April 2011

Keywords provided by Weill Medical College of Cornell University:


Thalassemia hypercalciuria vitamin D To conduct a pilot study to determine the effect of various doses of vitamin D supplementation on vitamin D stores and their association with calcium excretion

Additional relevant MeSH terms:

Layout table for MeSH terms

Thalassemia beta-Thalassemia Anemia, Hemolytic, Congenital Anemia, Hemolytic Anemia Hematologic Diseases Hemoglobinopathies Genetic Diseases, Inborn	Vitamin D Cholecalciferol Vitamins Micronutrients Physiological Effects of Drugs Bone Density Conservation Agents Calcium-Regulating Hormones and Agents

To Top